The future of incretin-based therapy: novel avenues-novel targets.

Research output: Contribution to journalArticlepeer-review


Incretin-based therapy for type 2 diabetes is based on the antidiabetic effects of glucagon-like peptide-1 (GLP-1) and instituted by GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors targeting the key islet defects of the disease. The treatment is clinically efficient and safe, and associated with a low risk of adverse events. It can be used both in early and late stages of the disease and both as monotherapy and add-on to other therapies. Current research on the future of incretin-based therapy focuses on optimizing its place in diabetes treatment and examines its potential in type 1 diabetes, in subjects with obesity without type 2 diabetes and in cardiovascular and neurodegenerative disorders. Other studies aim at prolonging the duration of action of the GLP-1 receptor agonists to allow weekly administration, and to develop orally GLP-1 receptor agonists. Furthermore, other investigators focus on stimulation of GLP-1 secretion by activating GLP-1-producing L-cells or using gene therapy. Finally, also other gastro-entero-pancreatic bioactive peptides are potential targets for drug development as are synthetic peptides engineered as co-agonists stimulating more than one receptor. We can therefore expect a dynamic development within this field in the coming years.
Original languageEnglish
Pages (from-to)158-166
JournalDiabetes, Obesity and Metabolism
Volume13 Suppl 1
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Endocrinology and Diabetes


Dive into the research topics of 'The future of incretin-based therapy: novel avenues-novel targets.'. Together they form a unique fingerprint.

Cite this